In contrast, a recent large multisite cohort study across six countries found no significant association between GLP-1 RA use and thyroid cancer compared with DPP-4 inhibitors (HR 0.81; 95% CI, 0.59–1.12), and no dose–response relationship was observed [12]. This evidence concerns the gene GLP1R and thyroid gland carcinoma.